Patients with Core-Binding Factor (CBF), characterized by the t(8;21) translocation and inversion inv(16)/t(16;16), and their molecular equivalents, RUNX1::RUNX1T1 and CBFB::MYH11, and NPM1-mutated acute myeloid leukemia (AML) are considered as favorable or intermediate-risk according to the 2022 European LeukemiaNet (ELN) classification [1]. This evidence concerns the gene NPM1 and acute myeloid leukemia.